PRELIMINARY SCIENTIFIC PROGRAM

SCIENTIFIC PLANNING COMMITTEE

CO-CHAIRS

Pier Francesco Ferrucci – Istituto Europeo di Oncologia, Milano, IT
Christoph Huber – Association for Cancer Immunotherapy, Mainz, DE
Arlene Sharpe - Harvard Medical School, Boston, MA, USA
Padmanee Sharma - MD Anderson Cancer Center, Houston, TX, USA

COMMITTEE

Mustafa Diken - Johannes Gutenberg University, Mainz, DE
Marina Garassino – University of Chicago, Chicago, IL, USA
Sue Kaech – Salk Institute for Biological Studies, La Jolla, CA, USA
Nir Hacohen, Harvard Medical School, MA, USA
Paola Nisticò – Regina Elena National Cancer Institute, Roma, IT
Pamela Ohashi – University of Toronto, Toronto, CAN
Catherine Sautès-Fridman – Paris Descartes University, Paris, FR
Andrea Schietinger – Sloan Kettering Institute, New York, NY, USA
Özlem Türeci - BioNTech, Mainz, DE
Cassian Yee - MD Anderson Cancer Center, Houston TX, USA
Laurence Zitvogel – Gustave Roussy Institute, Villejuif, FR

LOCAL ORGANISING COMMITTEE

Paola Allavena - Humanitas Research Hospital, Milano
Paolo Ascierto – Istituto Nazionale Tumori, Napoli
Matteo Bellone – San Raffaele Scientific Institute, Milano
Vincenzo Bronte – Istituto Oncologico Veneto, Padova
Giulia Casorati – San Raffaele Scientific Institute, Milano
Anna Mondino – San Raffaele Scientific Institute, Milano
Vincenzo Russo – San Raffaele Scientific Institute, Milano
Antonio Sica – Humanitas Research Hospital, Milano
Claudio Tripodo – University of Palermo, Palermo
Day 1 - Wednesday, September 20, 2023

2.00 – 2.40 pm  
**ENCI-AIRC Lecture**

Jim Allison – The University of Texas MD Anderson Cancer Centre (USA)
*Immune Checkpoint Blockade in Cancer Therapy: historical perspective, new opportunities, and prospects for cures*

2.40 – 4.30 pm  
**Session 1: With a little help from my friends: innate immune cells and stromal cells in the tumor microenvironment**

Lisa Coussens - Knight Cancer Institute (USA)
*Immune Vulnerabilities in Solid Tumors: Leukocyte Communication Networks Regulate Neoplastic Progression and Response to Therapy*

Eric Vivier - Aix Marseille Université – INSERM - CNRS (France)
*Harnessing Innate Immunity in Cancer Therapy*

* tbd

2 Proffered talks

4.30 – 6.15 pm  
**Session 2: Deranged T and B cells within the tumor microenvironment**

Catherine Sautès-Fridman - University Paris Cité (France)
*TLS and B cells in the immunotherapy response*

Andrea Schietinger - Sloan Kettering Institute (USA)

Yifat Merbl - Weizmann Institute (Israel)
*Proteasomal profiling: From global views of degradation to novel mechanisms of anti-tumor immunity*

2 Proffered talks

6.15 – 7.00 pm  
**William B. Coley Lecture**

Tak Wah Mak – University of Toronto (Canada)
Day 2 - Thursday, September 21, 2023

8.30 – 10.15 am Round table 1: **Lung cancer at the forefront of cancer immunotherapy**
Marina Garassino – University of Chicago (USA)
*Beyond PD-L1 in NSCLC*

**Sergio Quezada** – UCL Cancer Institute – University (UK)
*Regulatory T cell targeting at the interface of adaptive and innate function within tumours*

**Diether Lambrechts** – KU Leuven Center for Cancer Biology (Belgium)
*Unraveling Tumor Immune responses during checkpoint immunotherapy using single-cell and spatial technologies*

2 Proffered talks

General discussion

10.15 – 10.45 am Break

10.45 – 12.30 pm Round table 2: **Harnessing immunotherapy against breast cancer**
Marleen Kok – Netherlands Cancer Institute (The Netherlands)
*Improving immunotherapy for breast cancer patients*

**Fatima Mechta-Grigoriou** – Institut Curie (France)
*Mapping stromal heterogeneity in breast cancer*

**Silvia Formenti** – Weill Cornell Medicine (New York)

2 Proffered talks

General discussion

12.30 – 2.00 pm **Industry lunch meeting and poster session**

2.00 – 2.40 pm **Pezcoller Lecture**
**Alberto Mantovani** – Humanitas Research Insitute (Italy)
*Innate Immunity, Inflammation and Cancer: double edged swords*

2.50 – 4.20 pm **Session 3: The earlier the better: neoadjuvant immunotherapy against cancer**
**Padmanee Sharma** – MD Anderson Cancer Center (USA)
*Immune Checkpoint Therapy: Identifying Mechanisms of Response and Resistance*
Christian Blank – The Netherlands Cancer Institute (The Netherlands)
*Neoadjuvant Immunotherapy – next steps towards total personalization*

Tina Cascone – MD Anderson Cancer Center (USA)
*Advances in neoadjuvant and perioperative immunotherapy for lung cancer*

----------------------------------

1 Proffered talk

4.20 – 4.40 pm  Break

4.40 – 6.35 pm  Session 4: *Technologies, technologies, technologies: we need more*

Nir Hacohen – Harvard Medical School (USA)
*Spatial Organization of the Immune Response in Tumors*

Aaron Newman – Stanford Cancer Institute (USA)
*Big data approaches for immuno-oncology*

Joakim Lundeberg - KTH Royal Institute of Technology (Sweden)
*The cancer ecosystems captured by spatially resolved omics*

----------------------------------

1 Proffered talk

Day 3 – Friday, September 22, 2023

8.30 – 10.15 am  Round table 3: *How to overcome resistance of poorly sensitive tumors to immunotherapy*

Andrea Alimonti – Università della Svizzera Italiana (Switzerland)
*Targeting senescent tumors and immune cells for effective cancer therapy*

Vincenzo Bronte – Istituto Oncologico Veneto (Italy)
*The cold immune environment in pancreatic cancer*

Özlem Türeci – BioNTech (Germany)
*mRNA-based immunotherapies*

----------------------------------

2 Proffered talks

General discussion

10.15 – 10.35 am  Break

10.35 – 12.45 pm  Round table 4: *Melanoma immunotherapy – learning from failure and success*

Tom Gajewski - The University of Chicago (USA)
Paolo Ascierto  - Università degli Studi di Napoli Federico II (Italy)
Combination strategy to overcome resistance

Jeffrey Weber  - NYU Langone New York (USA)
Neo-antigen vaccines with checkpoint inhibition: a novel adjuvant strategy for melanoma and other cancers.

-------------------------------
2 Proffered talks

General discussion

12.45 – 2.00 pm  Industry lunch meeting and poster session

2.00 – 4.10 pm  Session 5: Metabolic barriers to cancer immunotherapy
Guido Kroemer  - Université de Paris (France)
Improving the cancer-immune crosstalk by caloric restriction mimetics

Susan Kaech  - Salk Institute for Biological Studies (USA)
Nutritional influence on T cell exhaustion

Antonio Sica  - University of Eastern Piedmont (Italy)
Metabolic dysregulation of myelopoiesis in cancer

Greg Delgoffe  - University of Pittsburgh (USA)
Metabolic inputs and outputs of exhausted T cells in cancer

-------------------------------
2 Proffered talk

4.10 – 4.30 pm  Break

4.30 – 6.15 pm  Session 6: Determinants of response to immunotherapy
Arlene Sharpe  - Harvard Medical School (USA)
Overcoming microbiome-related resistance to PD-1/PD-L1 cancer immunotherapy

Paola Nisticò – IFO Regina Elena National Cancer Institute (Italy)
hMENA isoforms as architects of lung tumor immune microenvironment and determinants of immunotherapy response

Ira Mellman  – Genentech (USA)

-------------------------------
2 Proffered talks
Day 4 – Saturday, September 23, 2023

8.15 – 9.00 am  **AACR Keynote Lecture**
TBD

9.00 – 10.15 am  **Round table 5: What we can learn from hematologic malignancies**
Chiara Bonini – IRCCS Ospedale San Raffaele (Italy)
*Multiple genome editing for cancer immunotherapy with engineered lymphocytes*

Max Topp - Universitätsklinikum Würzburg (Germany)

Matteo Bellone - IRCCS Ospedale San Raffaele (Italy)
*Impact of diet and microbiota on immunotherapy for plasma cell dyscrasias*

General discussion

10.15 – 10.35 am  **Break**

10.35 am – 12.05 pm  **Session 7: Bang on target: modulating the microbiota to improve cancer immunotherapy**
Florence McAllister – MD Anderson Cancer Center (USA)
*Tumor resident microbes influencing immune responses*

Laurence Zitvogel - Gustave Roussy Cancer Campus (France)
*Microbiota-dependent emigration of enterotropic T cells to tumors*

Kathy McCoy - University of Calgary (Canada)
*Identifying microbes and metabolites that modulate cancer immunotherapy to translate discovery to treatment*

-------------------------------
1 Proffered talk

12.05 – 1.50 pm  **Session 8: Cellular therapies: arming immune cells**
George Coukos – University of Lausanne (Switzerland)

Cassian Yee - University of Texas (USA)
*TCR-based Tumor Agnostic Cell Therapy*

Gianpietro Dotti - University of North Carolina Lineberger Comprehensive Cancer Center

-----------------------------------
2 Proffered talks

1.50 - 2.00 pm  **Closing remarks and meeting ends**